1963

MS&D begins shipping its live-virus measles vaccine, trade marketed Rubeovax – which had to be administered with standardized immune globulin – trademarked Gammagee; in 1967, it released a combination measles/smallpox vaccine (Dryvax), and in 1968 it released a more attenuated live measles virus vaccine (Attenuvax) that did not require coadministration of immune globulin (Galambos & Sewell, 96-98).